GRCE
Grace Therapeutics, Inc.
Biotechnology
Market Cap$35M
5Y Perf.-29.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
GRCE vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$652M
5Y Perf.-61.4%
GRCE vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | GRCE | ARVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $35M | $652M |
| Revenue (TTM) | $0.00 | $263M |
| Net Income (TTM) | $-6M | $-81M |
| Gross Margin | — | 99.5% |
| Operating Margin | — | -44.0% |
| Total Debt | $0.00 | $9M |
| Cash & Equiv. | $22M | $143M |
GRCE vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
GRCE
ARVN
| Stock | Oct 24 | May 26 | Return |
|---|---|---|---|
| Grace Therapeutics,… (GRCE) | 100 | 70.3 | -29.7% |
| Arvinas, Inc. (ARVN) | 100 | 38.6 | -61.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GRCE vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: GRCE leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Arvinas, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
GRCE
Grace Therapeutics, Inc.
The Income Pick
GRCE carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.87
- EPS growth 54.3%
- -25.2% 10Y total return vs ARVN's -36.5%
Best for: income & stability and growth exposure
ARVN
Arvinas, Inc.
The Momentum Pick
ARVN is the clearest fit if your priority is momentum.
- +52.8% vs GRCE's -25.5%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | GRCE | 55.3% revenue growth vs ARVN's -0.3% |
| Quality / Margins | GRCE | 1.0% margin vs ARVN's -30.8% |
| Stability / Safety | GRCE | Beta 0.87 vs ARVN's 1.15 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ARVN | +52.8% vs GRCE's -25.5% |
| Efficiency (ROA) | GRCE | -8.7% ROA vs ARVN's -9.3%, ROIC -30.1% vs -22.4% |
GRCE vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
GRCE vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGRCELAGGINGARVN
ARVNArvinas, Inc.
1leads
GRCEGrace Therapeutics, I…
2leads
6 Total Categories
CATEGORYLEADERvs ARVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GRCE1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARVN4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
GRCE4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GRCE leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARVN and GRCE operate at a comparable scale, with $263M and $0 in trailing revenue.
| Metric | GRCEGrace Therapeutic… | ARVNArvinas, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $263M |
| EBITDAEarnings before interest/tax | -$9M | -$111M |
| Net IncomeAfter-tax profit | -$6M | -$81M |
| Free Cash FlowCash after capex | -$10M | -$276M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | -44.0% |
| Net MarginNet income ÷ Revenue | — | -30.8% |
| FCF MarginFCF ÷ Revenue | — | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +61.1% | -65.1% |
GRCE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — GRCE and ARVN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | GRCEGrace Therapeutic… | ARVNArvinas, Inc. |
|---|---|---|
| Market CapShares × price | $35M | $652M |
| Enterprise ValueMkt cap + debt − cash | $13M | $517M |
| Trailing P/EPrice ÷ TTM EPS | -2.85x | -7.96x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.48x |
| Price / BookPrice ÷ Book value/share | 0.41x | 1.52x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — GRCE and ARVN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ARVN leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
GRCE delivers a -9.2% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-14 for ARVN. On the Piotroski fundamental quality scale (0–9), ARVN scores 4/9 vs GRCE's 1/9, reflecting mixed financial health.
| Metric | GRCEGrace Therapeutic… | ARVNArvinas, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -9.2% | -14.3% |
| ROA (TTM)Return on assets | -8.7% | -9.3% |
| ROICReturn on invested capital | -30.1% | -22.4% |
| ROCEReturn on capital employed | -23.5% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | — | 0.02x |
| Net DebtTotal debt minus cash | -$22M | -$134M |
| Cash & Equiv.Liquid assets | $22M | $143M |
| Total DebtShort + long-term debt | $0 | $9M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
ARVN leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
GRCE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GRCE five years ago would be worth $7,475 today (with dividends reinvested), compared to $1,601 for ARVN. Over the past 12 months, ARVN leads with a +52.8% total return vs GRCE's -25.5%. The 3-year compound annual growth rate (CAGR) favors GRCE at -9.2% vs ARVN's -25.5% — a key indicator of consistent wealth creation.
| Metric | GRCEGrace Therapeutic… | ARVNArvinas, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -38.5% | -11.2% |
| 1-Year ReturnPast 12 months | -25.5% | +52.8% |
| 3-Year ReturnCumulative with dividends | -25.2% | -58.7% |
| 5-Year ReturnCumulative with dividends | -25.2% | -84.0% |
| 10-Year ReturnCumulative with dividends | -25.2% | -36.5% |
| CAGR (3Y)Annualised 3-year return | -9.2% | -25.5% |
GRCE leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — GRCE and ARVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
GRCE is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than ARVN's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARVN currently trades 70.2% from its 52-week high vs GRCE's 43.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | GRCEGrace Therapeutic… | ARVNArvinas, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.15x |
| 52-Week HighHighest price in past year | $5.18 | $14.51 |
| 52-Week LowLowest price in past year | $1.79 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +43.4% | +70.2% |
| RSI (14)Momentum oscillator 0–100 | 33.1 | 42.6 |
| Avg Volume (50D)Average daily shares traded | 886K | 808K |
Evenly matched — GRCE and ARVN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | GRCEGrace Therapeutic… | ARVNArvinas, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $13.00 |
| # AnalystsCovering analysts | — | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.1% |
Insufficient data to determine a leader in this category.
Key Takeaway
GRCE leads in 2 of 6 categories (Income & Cash Flow, Total Returns). ARVN leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallGrace Therapeutics, Inc. (GRCE)Leads 2 of 6 categories
Loading custom metrics...
GRCE vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is GRCE or ARVN a better buy right now?
Analysts rate Arvinas, Inc.
(ARVN) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — GRCE or ARVN?
Over the past 5 years, Grace Therapeutics, Inc.
(GRCE) delivered a total return of -25. 2%, compared to -84. 0% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: GRCE returned -25. 2% versus ARVN's -36. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — GRCE or ARVN?
By beta (market sensitivity over 5 years), Grace Therapeutics, Inc.
(GRCE) is the lower-risk stock at 0. 87β versus Arvinas, Inc. 's 1. 15β — meaning ARVN is approximately 32% more volatile than GRCE relative to the S&P 500.
04Which is growing faster — GRCE or ARVN?
On earnings-per-share growth, the picture is similar: Grace Therapeutics, Inc.
grew EPS 54. 3% year-over-year, compared to 53. 8% for Arvinas, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — GRCE or ARVN?
Grace Therapeutics, Inc.
(GRCE) is the more profitable company, earning 0. 0% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GRCE leads at 0. 0% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — GRCE or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is GRCE or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Grace Therapeutics, Inc.
(GRCE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (GRCE: -25. 2%, ARVN: -36. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between GRCE and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.